Alkem Laboratories today launched a patented technology for the treatment of Diabetic Foot Ulcer (DFU) for the first time in India. The solution would be based on disruptive 4D-bioprinting technology, which would be used to treat deep, non-healing chronic wounds, and is expected to be launched in the Indian market in the latter half of 2022 post-regulatory approval, a statement from Alkem said.
This technology for DFU management has a high scope of preventing amputations in diabetic patients. It will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India, it further said.
According to the statement, Alkem has collaborated with Rokit Healthcare Inc to commercialise the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient’s quality of life and the associated economic burden on the healthcare system.
Last news about this category